RECURSION PHARMACEUTICALS, INC. (RXRX) insider trading

Insider

Date

Role

Action

Shares

Price

Amount

Blake Borgeson

3 Nov 2026

Director

Sold on a plan

40,000

$3.88

$155.20K

Blake Borgeson

6 Oct 2026

Director

Sold on a plan

50,000

$4.84

$242.00K

Najat Khan

8 Sep 2026

CEO and President

Sold on a plan

22,408

$3.52

$78.82K

Blake Borgeson

1 Sep 2026

Director

Sold on a plan

30,000

$3.34

$100.20K

Blake Borgeson

4 Aug 2026

Director

Sold on a plan

30,000

$3.25

$97.50K

Blake Borgeson

7 Jul 2026

Director

Sold on a plan

40,000

$3.96

$158.50K

Namandje Bumpus

18 Jun 2026

Director

Sold on a plan

3,963

$3.18

$12.60K

Najat Khan

5 Jun 2026

CEO and President

Sold on a plan

23,588

$3.58

$84.46K

Namandje Bumpus

3 Jun 2026

Director

Sold on a plan

4,386

$3.54

$15.53K

Blake Borgeson

2 Jun 2026

Director

Sold on a plan

30,000

$3.68

$110.40K

Blake Borgeson

5 May 2026

Director

Sold on a plan

30,000

$3.52

$105.60K

Blake Borgeson

7 Apr 2026

Director

Sold on a plan

30,000

$3.10

$93.00K

Ben R Taylor

17 Mar 2026

Chief Financial Officer

Sold on a plan

7,956

$3.39

$26.97K

Najat Khan

9 Mar 2026

CEO and President

Sold on a plan

28,298

$3.35

$94.66K

Blake Borgeson

3 Mar 2026

Director

Sold on a plan

170,000

$3.46

$588.20K

Ben R Taylor

18 Feb 2026

Chief Financial Officer

Sold on a plan

13,426

$3.08

$41.35K

Blake Borgeson

3 Feb 2026

Director

Sold on a plan

220,000

$4.20

$924.00K

Blake Borgeson

6 Jan 2026

Director

Sold on a plan

220,000

$4.36

$959.20K

Ben R Taylor

29 Dec 2025

Chief Financial Officer

Sold on a plan

21,383

$4.18

$89.38K

Najat Khan

22 Dec 2025

Chief R&D Commercial Officer

Sold on a plan

124,403

$4.41

$548.59K

Blake Borgeson

2 Dec 2025

Director

Sold on a plan

220,000

$4.37

$961.40K

RECURSION PHARMACEUTICALS, INC.

What the insiders did Scheduled selling only

Individual transactions

What was left out